Can Bee Venom Peptides Help Fight Cancer? A Systematic Review of Apamin and Melittin Conjugates

Systematic review of preclinical studies examining apamin and melittin conjugates in cancer treatment. The authors followed systematic review methodology to identify, screen, and synthesize studies on bee venom-derived peptide conjugates and their anti-cancer properties across various tumor models.

Cancer drugs often fail because they can't reach tumors effectively or because cancer cells develop resistance. Bee venom peptides like melittin naturally disrupt cell membranes, which can be weaponized to selectively attack cancer cells. This review consolidates the preclinical evidence showing these peptides work as delivery enhancers and tumor-targeting agents — a fundamentally different approach from traditional chemotherapy.

Peptide-drug conjugates are one of the fastest-growing areas in cancer research. While most attention goes to antibody-drug conjugates, venom-derived peptides offer a smaller, cheaper, and potentially more versatile alternative. Melittin's natural ability to punch holes in cell membranes makes it uniquely suited for getting drugs inside cancer cells. This review maps where the field stands and what gaps remain before these approaches can reach patients.

All included studies were preclinical — no human clinical trials have been conducted yet. The review covers multiple cancer types and conjugate formulations, making it difficult to draw conclusions about any single approach. Publication bias toward positive results is likely. The jump from preclinical promise to clinical reality remains unproven for these peptides.